Asker Healthcare Group Ab · OMXSTO:ASKER
Asker Healthcare Group Ab — Q2 2026 Earnings Presentation
16 slides from Asker Healthcare Group Ab's earnings presentation, Jul 21, 2026
Slide 1: Q2 Interim Report January–June 2026: Continued steady growth
Q2 INTERIM REPORT JANUARY – JUNE 2026 Continued steady growth Johan Falk, CEO Thomas Moss, CFO 1
Slide 2: Q2 Highlights Q2 2026
Q2 Highlights Q2 2026 • Continued steady organic growth ahead of the market, with increasing margin expansion as we scale ADJ. EBITA GROWTH • Net sales of SEK 4,686m, up 18% of which 5% organic • Adj. EBITA of SEK 471m, up 24%, of which 6% organic 24% of which 6% organic • Adj. EBITA margin strength
Slide 3: Delivering on our financial targets
+21% +69% Adj. EBITA R/RK (EBITA/NWC) Delivering on our growth per year financial targets LTM 2025/2026 TARGET >15% TARGET >50% 9.8% 2.37x Adj. EBITA margin Net Debt/EBITDA* TARGET (medium term) >10% TARGET <2.5x 3 *Adjusted for leases and items affecting comparability
Slide 4: Continuing to deliver stable and profitable total EBITA growth quarter over quarter
Continuing to deliver stable and profitable total EBITA growth quarter over quarter Adj. EBITA R121) SEKm 1,765 >15% CAGR 317 Q1 Q1 Q1 Q1 Q1 Q1 Q1 2020 2021 2022 2023 2024 2025 2026 4 1) EBITA excl. items affecting comparability and estimated Covid-19 effect ’20-‘22.
Slide 5: Financial performance – Group
Financial performance – Group Continued solid growth Amounts in Q2 Q2 Jan–Jun Jan–Jun LTM January – June 2026 SEKm 2026 2025 2026 2025 25/26 Adj. EBITA growth Net sales 4,686 3,987 9,207 7,982 18,012 30% 18% 25% 23% Adj. EBITA 471 378 912 742 1,765 -2% 20% Adj. EBITA 10.0% 9.5% 9.9% 9.3% 9.8% 15% ma
Slide 6: Business Area North
Business Area North Business in North continues to perform well with good organic growth Amounts in Q2 2026 Q2 2025 Jan–Jun Jan–Jun LTM January – June 2026 SEKm 2026 2025 25/26 • Adj. EBITA growth 8% Net sales 1,429 1,265 2,783 2,527 5,465 ⎯ Organic growth of 5% ⎯ Acquired growth of 3% Adj. EBITA 19
Slide 7: Business Area West
Business Area West Another quarter of strong growth in West Amounts in Q2 2026 Q2 2025 Jan–Jun Jan–Jun LTM January – June 2026 SEKm 2026 2025 25/26 • Adj. EBITA growth 32% Net sales 2,327 2,021 4,580 4,029 9,095 ⎯ Organic growth of 12% ⎯ Acquired growth of 23% Adj. EBITA 224 169 438 330 864 ⎯ Exchan
Slide 8: Business Area Central
Business Area Central Continued strengthening of results and positive development of margins Amounts in Q2 2026 Q2 2025 Jan–Jun Jan–Jun LTM January – June 2026 SEKm 2026 2025 25/26 • Adj. EBITA growth 52% Net sales 931 701 1,844 1,426 3,452 ⎯ Organic growth of 14% ⎯ Acquired growth of 40% Adj. EBITA
Slide 9: R/RK improved from a high level
R/RK improved from a high level R/RK • R/RK amounted to 68.7% (65.4) 100% • Continued efficient working capital utilisation across all business area 80% 60% 40% 20% 0% Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 R/RK (EBITA/NWC) Asker target >50% 9
Slide 10: Robust cash flow with good visibility and control over future outflows
Robust cash flow with good visibility and control over future outflows Amounts in SEKm Q2 Q2 Jan–Jun Jan–Jun LTM Jan–Dec • Adj. cash flow from operating activities 2026 2025 2026 2025 25/26 2025 SEK 330m (211) in Q2 Adj cash flow from 330 211 7749 320 1,814 1,385 operating activities • CAPEX for DC
Slide 11: Stable leverage below target level, allowing for continued acquisitions
Stable leverage below target level, allowing for continued acquisitions Amounts in SEKm 30 June 2026 30 June 2025 • Leverage marginally and temporarily elevated after larger cash outflows in Q2 but continues at a level Net debt 4,511 2,886 that ensures capacity for M&A agenda EBITDA* 1,900 1,566 Net
Slide 12: Ahead of our 2026 M&A target
Ahead of our 2026 M&A target Month Business Annual sales, completed Acquisition Area SEKm* July Murray Surgical West 73 • Acquisition of Murray Surgical completed on YTD 2026 April RMS Medical Devices West 170 3 July 2026, adding SEK 73m in annual sales February GHC/MPF Central 300 • Kirstine Hardam
Slide 13: Explore an acquisition - RMS Medical Devices closed in April
Explore an acquisition - RMS Medical Devices closed in April • Combines strong clinical expertise in endoscopy, radiology and urology with rapidly expanding activities in digital health, artificial intelligence and minimally invasive surgery • 40 years of experience in the Belgian healthcare market
Slide 14: Q2 in summary
Q2 in summary • Continued steady organic growth ahead of the market, and good contribution from acquisitions to both growth and margin ⎯ 24% total adjusted EBITA growth, whereof 6% organic • Adjusted EBITA margin strengthened to 10.0% • Continued good and robust cash flow • High-quality acquisitions
Slide 15: Q&A
Q&A
Slide 16: Financial calendar
Financial calendar • Q3 report 4 Nov 2026 • Year-end report 2026 10 Feb 2027 We are health Additional information in progress Thomas Moss, CFO and Head of IR Tel: +46 70 219 79 05 • Improve patient outcome • Reduce total cost of care ir@asker.com • Ensure a fair and sustainable value chain
Asker Healthcare Group — Q2 2026 Earnings Presentation on 6ix